HazemYacoub
@hazemyacoub.bsky.social
Since its creation in 2023, the UPC has been quietly reshaping patent strategies.
However, pharma companies that ignore its influence and interactions with other European courts will find themselves struggling to adapt.
However, pharma companies that ignore its influence and interactions with other European courts will find themselves struggling to adapt.
New IAM Special Report scrutinises the strategic and commercial impact of the UPC
Leading experts share how Europe’s new court is transforming the playbook for corporates and IP litigators around the world
www.iam-media.com
January 23, 2026 at 8:36 AM
Since its creation in 2023, the UPC has been quietly reshaping patent strategies.
However, pharma companies that ignore its influence and interactions with other European courts will find themselves struggling to adapt.
However, pharma companies that ignore its influence and interactions with other European courts will find themselves struggling to adapt.
CMOs and pharma companies are experiencing a capacity crunch, where, for one reason or another, they lack the capacity and capabilities to meet demand.
While it's impossible to eradicate this issue entirely, there are ways to minimize it. The earlier they're adopted, the better.
While it's impossible to eradicate this issue entirely, there are ways to minimize it. The earlier they're adopted, the better.
A Deeper Look At Pharma's Structural Supply Chain Vulnerability
Fixing limited capacity in pharmaceutical CMC development starts with understanding a complex web of root causes.
www.outsourcedpharma.com
January 19, 2026 at 7:36 AM
CMOs and pharma companies are experiencing a capacity crunch, where, for one reason or another, they lack the capacity and capabilities to meet demand.
While it's impossible to eradicate this issue entirely, there are ways to minimize it. The earlier they're adopted, the better.
While it's impossible to eradicate this issue entirely, there are ways to minimize it. The earlier they're adopted, the better.
Do you plan to use AI in clinical trials? Focus on your data infrastructure before you do anything else.
Without updating our data strategies, it becomes much harder to use AI in any meaningful way. Data harmonization and integrated infrastructure will need to become a priority.
Without updating our data strategies, it becomes much harder to use AI in any meaningful way. Data harmonization and integrated infrastructure will need to become a priority.
Data Quality in Drug Development: The Missing Foundation to Realize AI’s Promise in Clinical Trials | PharmExec
AI’s transformative potential in clinical development relies on the industry's ability to rebuild its fractured data infrastructure.
www.pharmexec.com
January 16, 2026 at 7:52 AM
Do you plan to use AI in clinical trials? Focus on your data infrastructure before you do anything else.
Without updating our data strategies, it becomes much harder to use AI in any meaningful way. Data harmonization and integrated infrastructure will need to become a priority.
Without updating our data strategies, it becomes much harder to use AI in any meaningful way. Data harmonization and integrated infrastructure will need to become a priority.
76% of life sciences CEOs felt that their organizations were moving at the right speed to keep up with AI. That's partly because they make sure to invest in their people.
Without a commitment to upskilling, organizations will struggle to unlock AI's full potential.
Without a commitment to upskilling, organizations will struggle to unlock AI's full potential.
The Year of AI: 2025’s Bio/pharma Upskilling Revolution | Pharmaceutical Technology
In this look back at the year that was, in so many ways but in the bio/pharmaceutical industry especially, we remember 2025 as the point in time when AI declared it was here to stay.
www.pharmtech.com
January 12, 2026 at 7:16 AM
76% of life sciences CEOs felt that their organizations were moving at the right speed to keep up with AI. That's partly because they make sure to invest in their people.
Without a commitment to upskilling, organizations will struggle to unlock AI's full potential.
Without a commitment to upskilling, organizations will struggle to unlock AI's full potential.
What does AI mean for patentability in pharma?
As AI starts to play a bigger role in kickstarting innovation, IP legislation will need to evolve. Engaging in debates about what this should look like will give pharma companies a chance to shape it.
As AI starts to play a bigger role in kickstarting innovation, IP legislation will need to evolve. Engaging in debates about what this should look like will give pharma companies a chance to shape it.
January 9, 2026 at 6:01 AM
What does AI mean for patentability in pharma?
As AI starts to play a bigger role in kickstarting innovation, IP legislation will need to evolve. Engaging in debates about what this should look like will give pharma companies a chance to shape it.
As AI starts to play a bigger role in kickstarting innovation, IP legislation will need to evolve. Engaging in debates about what this should look like will give pharma companies a chance to shape it.
Are you ready for the next shift in AI?
2026 will be the year that pharma sees agentic AI really take off, making it important to prepare for this shift sooner rather than later.
2026 will be the year that pharma sees agentic AI really take off, making it important to prepare for this shift sooner rather than later.
2026: The year AI’s role in pharma shifts from analysis to action
2026 will mark AI’s evolution in pharma, turning intelligence into action across the value chain.
www.pharmavoice.com
December 31, 2025 at 6:57 AM
Are you ready for the next shift in AI?
2026 will be the year that pharma sees agentic AI really take off, making it important to prepare for this shift sooner rather than later.
2026 will be the year that pharma sees agentic AI really take off, making it important to prepare for this shift sooner rather than later.
As we get closer to the end of the year, don't forget to reevaluate your patent strategies.
As AI reshapes how we think about drug development, it'll also reshape the way we think about IP. Traditional strategies will become less relevant; so, don't leave your innovation unprotected!
As AI reshapes how we think about drug development, it'll also reshape the way we think about IP. Traditional strategies will become less relevant; so, don't leave your innovation unprotected!
December 26, 2025 at 9:01 AM
As we get closer to the end of the year, don't forget to reevaluate your patent strategies.
As AI reshapes how we think about drug development, it'll also reshape the way we think about IP. Traditional strategies will become less relevant; so, don't leave your innovation unprotected!
As AI reshapes how we think about drug development, it'll also reshape the way we think about IP. Traditional strategies will become less relevant; so, don't leave your innovation unprotected!
The patent cliff is looming, but AI could help soften the impact.
By using AI to accelerate and streamline R&D processes, companies could cut costs significantly. This would reduce the pressure that the patent cliff is creating.
By using AI to accelerate and streamline R&D processes, companies could cut costs significantly. This would reduce the pressure that the patent cliff is creating.
AI can reduce R&D costs to alleviate looming patent cliff pressures
Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent cliff pains.
www.clinicaltrialsarena.com
December 19, 2025 at 9:00 AM
The patent cliff is looming, but AI could help soften the impact.
By using AI to accelerate and streamline R&D processes, companies could cut costs significantly. This would reduce the pressure that the patent cliff is creating.
By using AI to accelerate and streamline R&D processes, companies could cut costs significantly. This would reduce the pressure that the patent cliff is creating.
A shift is taking place in the Middle East's biopharma sector.
Rather than simply selling medicines, companies and governments are focusing on building health systems. As a result, it's no longer enough for companies to think like businesses. They need to think like partners, too.
Rather than simply selling medicines, companies and governments are focusing on building health systems. As a result, it's no longer enough for companies to think like businesses. They need to think like partners, too.
Why biopharma must become a health system partner
Biopharma in the Middle East is shifting from selling medicines to building health systems through partnerships, digital tools, and real-world data
www.worldhealthexpo.com
December 15, 2025 at 6:57 AM
A shift is taking place in the Middle East's biopharma sector.
Rather than simply selling medicines, companies and governments are focusing on building health systems. As a result, it's no longer enough for companies to think like businesses. They need to think like partners, too.
Rather than simply selling medicines, companies and governments are focusing on building health systems. As a result, it's no longer enough for companies to think like businesses. They need to think like partners, too.
Whether you're developing an originator or a generic, it's always better to get regulatory approval right the first time.
By adopting the Quality by Design framework, companies can embed quality and scientific excellence into every stage of the process, paving the way for successful approvals.
By adopting the Quality by Design framework, companies can embed quality and scientific excellence into every stage of the process, paving the way for successful approvals.
December 10, 2025 at 7:17 AM
Whether you're developing an originator or a generic, it's always better to get regulatory approval right the first time.
By adopting the Quality by Design framework, companies can embed quality and scientific excellence into every stage of the process, paving the way for successful approvals.
By adopting the Quality by Design framework, companies can embed quality and scientific excellence into every stage of the process, paving the way for successful approvals.
Pharma companies are racing to deploy AI, but the real competition isn't who can cross the finish line first; it's who can get the right guardrails in place before AI projects go live.
Here are a few factors companies need to consider.
Here are a few factors companies need to consider.
Guardrails for AI in pharma, biotech and medtech | Grant Thornton
Explore expert insights on how pharma, biotech & medtech firms can deploy AI responsibly — balancing innovation, security & patient safety.
www.grantthornton.com
December 8, 2025 at 7:48 AM
Pharma companies are racing to deploy AI, but the real competition isn't who can cross the finish line first; it's who can get the right guardrails in place before AI projects go live.
Here are a few factors companies need to consider.
Here are a few factors companies need to consider.
The MENA market offers an excellent opportunity for pharma companies to expand, but taking advantage isn't as simple as importing your drugs.
Understanding local regulations and realities will help you make a splash without landing you in hot water with regulatory bodies.
Understanding local regulations and realities will help you make a splash without landing you in hot water with regulatory bodies.
How Do You Ensure Regulatory Compliance When Importing Drugs from India to Africa & MENA?
How do you ensure regulatory compliance when importing drugs from an Indian pharmaceutical manufacturer like Pyxus Pharma to Africa & MENA?
www.pyxuspharmaceuticals.com
December 5, 2025 at 7:16 AM
The MENA market offers an excellent opportunity for pharma companies to expand, but taking advantage isn't as simple as importing your drugs.
Understanding local regulations and realities will help you make a splash without landing you in hot water with regulatory bodies.
Understanding local regulations and realities will help you make a splash without landing you in hot water with regulatory bodies.
Drugs are becoming more complex, which means generics need to as well.
However, manufacturers should see this as an opportunity, not a barrier. Although complex generics have a higher barrier to entry, this also means manufacturers will face less competition, paving the way for growth.
However, manufacturers should see this as an opportunity, not a barrier. Although complex generics have a higher barrier to entry, this also means manufacturers will face less competition, paving the way for growth.
December 3, 2025 at 9:01 AM
Drugs are becoming more complex, which means generics need to as well.
However, manufacturers should see this as an opportunity, not a barrier. Although complex generics have a higher barrier to entry, this also means manufacturers will face less competition, paving the way for growth.
However, manufacturers should see this as an opportunity, not a barrier. Although complex generics have a higher barrier to entry, this also means manufacturers will face less competition, paving the way for growth.
77% of caregivers report routinely crushing tablets for patients with dysphagia, creating health risks and potentially reducing their efficacy.
Keeping this practice in mind when designing oral solid formulations can help manufacturers limit the harm this practice does to patients.
Keeping this practice in mind when designing oral solid formulations can help manufacturers limit the harm this practice does to patients.
Swallowing Safely: Evidence-Based Approaches to Tablets and Dysphagia
In stroke patients with dysphagia, the default practice of crushing tablets could increase residue, reduce efficacy, and raise aspiration risk. Researchers reveal how individualized FEES assessments can transform medication safety at the bedside.
themedicinemaker.com
December 1, 2025 at 7:56 AM
77% of caregivers report routinely crushing tablets for patients with dysphagia, creating health risks and potentially reducing their efficacy.
Keeping this practice in mind when designing oral solid formulations can help manufacturers limit the harm this practice does to patients.
Keeping this practice in mind when designing oral solid formulations can help manufacturers limit the harm this practice does to patients.
A strong portfolio suggestion report should be deep, relevant, and actionable. At Pi Pharma Intelligence, we dig into real data, tailor insights to your molecule and market, and focus on clear next steps.
Discover us here: www.pipharmaintelligence.com/
Discover us here: www.pipharmaintelligence.com/
November 28, 2025 at 7:15 AM
A strong portfolio suggestion report should be deep, relevant, and actionable. At Pi Pharma Intelligence, we dig into real data, tailor insights to your molecule and market, and focus on clear next steps.
Discover us here: www.pipharmaintelligence.com/
Discover us here: www.pipharmaintelligence.com/
Exciting news for Egypt’s pharmaceutical sector: Minapharm & Bayer have signed a strategic deal to boost local production in women’s and reproductive health. This cements Egypt’s role in high-tech pharmaceutical manufacturing.
'Minapharm' inks strategic coop. deal with German pharma giant 'Bayer'
<p>Minister of Health and Population Khaled Abdel Ghaffar attended the signing ceremony of a strategic cooperation agreement between Minapharm Pharmaceuticals, a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa, and Germany’s pharmaceutical and biotechnology giant "Bayer".</p>
<p>The deal, signed on the fringe of the 3rd edition of the
sis.gov.eg
November 26, 2025 at 7:30 AM
Exciting news for Egypt’s pharmaceutical sector: Minapharm & Bayer have signed a strategic deal to boost local production in women’s and reproductive health. This cements Egypt’s role in high-tech pharmaceutical manufacturing.
The future of healthcare in the Middle East is here, and it’s powered by omics. From prenatal testing to cancer care, genomics and proteomics are helping us predict, prevent, and personalize treatment like never before.
November 24, 2025 at 8:10 AM
The future of healthcare in the Middle East is here, and it’s powered by omics. From prenatal testing to cancer care, genomics and proteomics are helping us predict, prevent, and personalize treatment like never before.
Cross-border licensing is a chance to expand into new markets.
With access to the right patent data, you can spot the opportunities that best align with goals and take advantage of them before someone else does.
With access to the right patent data, you can spot the opportunities that best align with goals and take advantage of them before someone else does.
November 21, 2025 at 8:51 AM
Cross-border licensing is a chance to expand into new markets.
With access to the right patent data, you can spot the opportunities that best align with goals and take advantage of them before someone else does.
With access to the right patent data, you can spot the opportunities that best align with goals and take advantage of them before someone else does.
Variations in patent law can create headaches for global pharma companies. But by understanding these differences, companies can account for them and create tailored strategies that leverage the strengths of different jurisdictions to drive growth.
November 19, 2025 at 6:08 AM
Variations in patent law can create headaches for global pharma companies. But by understanding these differences, companies can account for them and create tailored strategies that leverage the strengths of different jurisdictions to drive growth.
A pilot scheme in the UK found that cutting liquid amoxicillin prescriptions by 23% reduced carbon emissions by 15%.
It's a powerful reminder that the demand for oral solid dosage forms isn't going to disappear.
Source: https://www.ljmu.ac.uk/about-us/news/articles/2025/10/31/children-and-pills
It's a powerful reminder that the demand for oral solid dosage forms isn't going to disappear.
Source: https://www.ljmu.ac.uk/about-us/news/articles/2025/10/31/children-and-pills
November 17, 2025 at 9:02 AM
A pilot scheme in the UK found that cutting liquid amoxicillin prescriptions by 23% reduced carbon emissions by 15%.
It's a powerful reminder that the demand for oral solid dosage forms isn't going to disappear.
Source: https://www.ljmu.ac.uk/about-us/news/articles/2025/10/31/children-and-pills
It's a powerful reminder that the demand for oral solid dosage forms isn't going to disappear.
Source: https://www.ljmu.ac.uk/about-us/news/articles/2025/10/31/children-and-pills
A pop of color can convey important technical detail in your patent application, but depending on the jurisdiction, it can also create some problems.
Being aware of how colored drawing requirements vary across the MENA region is essential for companies looking to expand into this new market.
Being aware of how colored drawing requirements vary across the MENA region is essential for companies looking to expand into this new market.
Navigating the Colorful World of Patent Drawings: A Comprehensive Global Perspective on Colored Drawing Requirements — Patent Panorama
The global landscape of patent illustration has undergone a remarkable transformation in recent years, with an increasing number of patent offices worldwide recognizing that colored drawings are essential for accurately disclosing complex innovations. What once represented exceptional accommodation
patentpanorama.com
November 14, 2025 at 9:03 AM
A pop of color can convey important technical detail in your patent application, but depending on the jurisdiction, it can also create some problems.
Being aware of how colored drawing requirements vary across the MENA region is essential for companies looking to expand into this new market.
Being aware of how colored drawing requirements vary across the MENA region is essential for companies looking to expand into this new market.
Oral solid dosage forms are still going strong, with demand for OSD oncology CDMOs continuing to rise.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
Oral Solid Dose Oncology CDMO Market Size, Report by 2034
The global oral solid dose oncology CDMO market is growing with rising demand for outsourced cancer drug manufacturing and advanced solid dosage formulation.
www.precedenceresearch.com
November 12, 2025 at 8:22 AM
Oral solid dosage forms are still going strong, with demand for OSD oncology CDMOs continuing to rise.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
The continued demand for home-based care will continue to fuel the need for oral dosage forms, and it's CDMOs that are helping pharma companies keep up as technology and regulation evolve.
Mobile manufacturing units have the potential to strengthen supply chain flexibility, but are they feasible for oral solid dosages?
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
November 10, 2025 at 6:55 AM
Mobile manufacturing units have the potential to strengthen supply chain flexibility, but are they feasible for oral solid dosages?
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
The smaller physical footprints of continuous OSD technologies make adapting to mobile manufacturing much simpler than other formulations.
In continuous manufacturing, changing throughputs often means you need to change machines, but by embracing modular process trains, this issue could soon disappear.
Q&A: Addressing practical challenges in CM
On 10th November at 9:00 AM - 9:30 AM CT, Sarang Oka, scientific fellow, Hovione, will do a talk titled "Addressing Practical Challenges in CM via Novel Hardware and Automation" at PharmSci360 in San Antonio, TX.
pharmaceuticalmanufacturer.media
November 7, 2025 at 7:46 AM
In continuous manufacturing, changing throughputs often means you need to change machines, but by embracing modular process trains, this issue could soon disappear.
India will be one of the earliest markets to face LoE for Semaglutide, but taking advantage will require generics companies to adapt their LoE playbooks.
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
November 5, 2025 at 9:02 AM
India will be one of the earliest markets to face LoE for Semaglutide, but taking advantage will require generics companies to adapt their LoE playbooks.
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook
Source: https://www.iqvia.com/locations/india/blogs/2025/10/semaglutide-loe-in-india-a-rare-opportunity-demanding-a-new-playbook